PrEP: A case study.
OBJECTIVE
The purpose of this case study is to present information and raise awareness about the provision of pre-exposure prophylaxis (PrEP) to those individuals who are at risk for HIV infection.


METHODS
PubMed, CINAHL, government websites, press releases, and the author's clinical experiences.


CONCLUSIONS
PrEP is the latest tool available for HIV prevention that has been approved by the FDA. It involves taking the HIV medication TDF/FTC on a daily basis. Documented side effects are minimal but renal monitoring is recommended because of possible kidney damage. PrEP may provide as much as 90% protection against HIV infection, but this is dependent upon patient compliance.


CONCLUSIONS
Nurse practitioners are in an ideal position to be the gatekeepers for information and access to PrEP. However, this requires that they engage in thorough risk assessments with their patients. This includes both a comprehensive sexual history and drug use history. The case study demonstrates the importance of intervention in and recognition of high-risk stigmatized populations such as transgender individuals and that prompt action may prevent future HIV infections.
School of Nursing and Health Professions, University of San Francisco, San Francisco, California.
Stefan
S
Rowniak
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000379:methods*; D000068679:Emtricitabine / Q000494:pharmacology / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy* / Q000517:prevention & control*; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D008297:Male; D040242:Risk Reduction Behavior; D021841:Safe Sex; D000068698:Tenofovir / Q000494:pharmacology / Q000627:therapeutic use
D019380:Anti-HIV Agents; D000068698:Tenofovir; D000068679:Emtricitabine
HIV/AIDS; gay health; nurse practitioners; prevention